Janssen's Sirukumab Brings Mortality Imbalance Into FDA Panel Review
Unfavorable trends in all-cause death, malignancy and major adverse cardiovascular events are key safety issues facing US agency's Arthritis Advisory Committee, which also is being asked to weigh adequacy of Janssen's dose selection and, more generally, use of long-term placebo controls in rheumatoid arthritis studies.
A mortality imbalance in clinical trials of Janssen Biotech Inc.'s rheumatoid arthritis (RA) treatment Plivensia (sirukumab) and other potential safety concerns will face scrutiny at an FDA advisory committee meeting Aug. 2.
FDA will ask its Arthritis Advisory Committee to weigh the safety of the biologic in light of unfavorable trends through...